- Email: [email protected]
Hyflux sets up joint venture in China
NEWS Editorial Office: Elsevier Advanced Technology PO Box 150, Kidlington Oxford OX5 1AS, UK Tel: +44 (0)1865 843239 Fax: +44 (0)1865 843971 Email: [email protected]
Technical Programme Editor: Steve Barrett
Editor: Simon Atkinson Tel/Fax: +44 (0)1865 751611 Email: [email protected]
Production Coordinator: Justin Hoffmann
Editorial advisory board: Dr P Ball (Pall Europe) Dr D Bessarabov (Kvaerner Chemetics, A Division of Kvaerner Canada Inc, Canada) Prof. M Cheryan (University of Illinois at Urbana-Champaign) Prof. A Fane (University of New South Wales) Dr T Franken (Membrane Application Centre Twente) Dr E Gobina (Robert Gordon University) Dr A Merry (PCI Membrane Systems) Prof. M Nyström (Lappeenranta University of Technology) Dr G Pearce (Kalsep) Dr P Pfromm (Institute of Paper Science & Technology, GA, USA) Dr R Philpott (Whatman International) Dr A Turner (AEA Technology) Prof. R Wakeman (Loughborough University of Technology) Prof. A Yaroshchuk (Ukrainian Academy of Sciences) Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail: permissions@ elsevier.com. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then ‘Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923, USA; tel: 978 7508400, fax: +1 978 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0) 171 436 5931; fax: +44 (0)171 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02095 Printed by Mayfield Press (Oxford) Ltd.
2
UV system is better than distillation Massachusetts-based Millipore Corporation has developed a water purification system which, it claims, offers numerous advantages over distillation. The company says that in contrast to this traditional water purification technique, its Elix ultraviolet (UV) system combines a number of purification technologies to provide users with clean water of consistent optimal quality. With distillation, specific ions and a number of organic molecules may be carried away with water vapor. As these contaminants distil or co-distil more easily than water, the quality of the purified water is compromised, says Millipore. The Elix system incorporates reverse osmosis, electrodeionization and germicidal UV lamp purification technologies that effectively remove ions, organics, particles and bacteria. The system produces pure water whose ionic quality for the majority of ions is equivalent – and in some cases superior – to the product water resulting from distillation, says the company. In addition, total organic carbon levels are significantly lower in the pure water produced by the Elix UV system than by distillation. The system is able to generate 10–4000 liters of pure water per day. The analytical-grade water that it produces meets the specifications for Type II water defined by ISO 3696/BS 3997. The water purification system uses easy-tochange cartridges and relies on an automatic cleaning process that does not require the use of a strong acid. Millipore says that users will also appreciate the system’s environment-friendly low water and electricity consumption that significantly reduces operating costs. Contact: Millipore Corporation, 290 Concord Road, Billerica, MA 01821, USA. Tel: +1 978 715 4321, Fax: +1 781 533 3110, www.millipore.com
Gas filter makes bioreactors safer The new Emflon CPFR sterilizing grade gas filter from US company Pall Corporation is specifically designed for demanding fermenter or bioreactor applications by enabling manufacturers to use oxygen enrichment processes more safely. An increasing number of life-saving protein-based therapies are produced from cells that are grown in bioreactors using oxygen-enriched air for aeration. Pall says that while oxygen enrichment improves production yields and lowers overall processing costs, it can increase potential fire risks in sterilizing gas filtration operations. Enrichment techniques can lead to safety challenges because elevated levels of oxygen in bioreactor airflows can increase the risk of spontaneous ignition of conventional air sterilizing filter materials. The Emflon CPFR filter membrane is constructed from polytetrafluoroethylene (PTFE) — a widely used material that does not readily ignite. Additionally, the filter’s support and drainage layers are designed using special materials to minimize combustibility, compared with polypropylene that is commonly used in the construction in other gas filters. As worldwide demand for fermentation and biotechnology products continues to rise, manufacturers are increasingly turning to oxygen enrichment techniques to maximize the levels of the gas that reaches cells, thereby promoting growth. More traditional technologies such as mechanical agitation or airlifting could be inefficient or not appropriate for certain types of cells (for example, mammalian cells used for biotechnology drug products) because they are sensitive to shear. The Emflon CPFR filter has been evaluated by the Federal Institute for Material Research and Testing (Bundesanstalt für Materialforschung und -prüfung) in Germany, which routinely tests materials for usage in gaseous oxygen. The filter materials were subjected to pressure shock tests with 100% gaseous oxygen at about 1 MPa (10 bar g), at a temperature of 60°C. The institute concluded that
the filter’s materials had a high combustion resistance under rigorous testing, and were suitable for microbial and mammalian cell culturing applications using oxygen enrichment. The filter is also integrity testable using a Water Intrusion Test, says Pall. Contact: Pall Corporation, 2200 Northern Boulevard, East Hills, NY 11548, USA. Tel: +1 516 484 5400, Fax: +1 516 484 3649, www.pall.com
Hyflux sets up joint venture in China Hyflux Ltd, a water treatment company based in Singapore, has signed a joint-venture deal with Beijing Shouren Group to develop water treatment projects in China, according to a report by the Channel NewsAsia agency. The agreement was signed by the company’s subsidiary Hyflux Filtech (Singapore) Pte Ltd, Beijing Shouren Group Co Ltd, Beijing Zhouji Investment Co Ltd and Beijing Shouren Shidai Investment Consulting Co. The joint venture will make and sell water treatment equipment and components, provide technical consultancy, and support and undertake water treatment engineering projects. According to Hyflux, it opens up opportunities to participate in municipal water treatment projects in a region that is facing a shortage of water, and is host to the Olympic Games in 2008. Ms Olivia Lum, Hyflux Group Chief Executive Officer and President, says: ‘With our combined strengths, this joint venture is positioned to be a strong player in the municipal water market, especially in Beijing and other parts of northern China.’ Hyflux Filtech will hold a 26% interest in the registered capital of the joint-venture company. Contact: Hyflux Group, 202 Kallang Bahru, Hyflux Building, Singapore 339339. Tel: +65 6214 0777, Fax: +65 6214 1211, Email: [email protected], www.hyflux.com
Membrane Technology June 2005
Technical Programme Editor: Steve Barrett
Editor: Simon Atkinson Tel/Fax: +44 (0)1865 751611 Email: [email protected]
Production Coordinator: Justin Hoffmann
Editorial advisory board: Dr P Ball (Pall Europe) Dr D Bessarabov (Kvaerner Chemetics, A Division of Kvaerner Canada Inc, Canada) Prof. M Cheryan (University of Illinois at Urbana-Champaign) Prof. A Fane (University of New South Wales) Dr T Franken (Membrane Application Centre Twente) Dr E Gobina (Robert Gordon University) Dr A Merry (PCI Membrane Systems) Prof. M Nyström (Lappeenranta University of Technology) Dr G Pearce (Kalsep) Dr P Pfromm (Institute of Paper Science & Technology, GA, USA) Dr R Philpott (Whatman International) Dr A Turner (AEA Technology) Prof. R Wakeman (Loughborough University of Technology) Prof. A Yaroshchuk (Ukrainian Academy of Sciences) Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail: permissions@ elsevier.com. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then ‘Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923, USA; tel: 978 7508400, fax: +1 978 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0) 171 436 5931; fax: +44 (0)171 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02095 Printed by Mayfield Press (Oxford) Ltd.
2
UV system is better than distillation Massachusetts-based Millipore Corporation has developed a water purification system which, it claims, offers numerous advantages over distillation. The company says that in contrast to this traditional water purification technique, its Elix ultraviolet (UV) system combines a number of purification technologies to provide users with clean water of consistent optimal quality. With distillation, specific ions and a number of organic molecules may be carried away with water vapor. As these contaminants distil or co-distil more easily than water, the quality of the purified water is compromised, says Millipore. The Elix system incorporates reverse osmosis, electrodeionization and germicidal UV lamp purification technologies that effectively remove ions, organics, particles and bacteria. The system produces pure water whose ionic quality for the majority of ions is equivalent – and in some cases superior – to the product water resulting from distillation, says the company. In addition, total organic carbon levels are significantly lower in the pure water produced by the Elix UV system than by distillation. The system is able to generate 10–4000 liters of pure water per day. The analytical-grade water that it produces meets the specifications for Type II water defined by ISO 3696/BS 3997. The water purification system uses easy-tochange cartridges and relies on an automatic cleaning process that does not require the use of a strong acid. Millipore says that users will also appreciate the system’s environment-friendly low water and electricity consumption that significantly reduces operating costs. Contact: Millipore Corporation, 290 Concord Road, Billerica, MA 01821, USA. Tel: +1 978 715 4321, Fax: +1 781 533 3110, www.millipore.com
Gas filter makes bioreactors safer The new Emflon CPFR sterilizing grade gas filter from US company Pall Corporation is specifically designed for demanding fermenter or bioreactor applications by enabling manufacturers to use oxygen enrichment processes more safely. An increasing number of life-saving protein-based therapies are produced from cells that are grown in bioreactors using oxygen-enriched air for aeration. Pall says that while oxygen enrichment improves production yields and lowers overall processing costs, it can increase potential fire risks in sterilizing gas filtration operations. Enrichment techniques can lead to safety challenges because elevated levels of oxygen in bioreactor airflows can increase the risk of spontaneous ignition of conventional air sterilizing filter materials. The Emflon CPFR filter membrane is constructed from polytetrafluoroethylene (PTFE) — a widely used material that does not readily ignite. Additionally, the filter’s support and drainage layers are designed using special materials to minimize combustibility, compared with polypropylene that is commonly used in the construction in other gas filters. As worldwide demand for fermentation and biotechnology products continues to rise, manufacturers are increasingly turning to oxygen enrichment techniques to maximize the levels of the gas that reaches cells, thereby promoting growth. More traditional technologies such as mechanical agitation or airlifting could be inefficient or not appropriate for certain types of cells (for example, mammalian cells used for biotechnology drug products) because they are sensitive to shear. The Emflon CPFR filter has been evaluated by the Federal Institute for Material Research and Testing (Bundesanstalt für Materialforschung und -prüfung) in Germany, which routinely tests materials for usage in gaseous oxygen. The filter materials were subjected to pressure shock tests with 100% gaseous oxygen at about 1 MPa (10 bar g), at a temperature of 60°C. The institute concluded that
the filter’s materials had a high combustion resistance under rigorous testing, and were suitable for microbial and mammalian cell culturing applications using oxygen enrichment. The filter is also integrity testable using a Water Intrusion Test, says Pall. Contact: Pall Corporation, 2200 Northern Boulevard, East Hills, NY 11548, USA. Tel: +1 516 484 5400, Fax: +1 516 484 3649, www.pall.com
Hyflux sets up joint venture in China Hyflux Ltd, a water treatment company based in Singapore, has signed a joint-venture deal with Beijing Shouren Group to develop water treatment projects in China, according to a report by the Channel NewsAsia agency. The agreement was signed by the company’s subsidiary Hyflux Filtech (Singapore) Pte Ltd, Beijing Shouren Group Co Ltd, Beijing Zhouji Investment Co Ltd and Beijing Shouren Shidai Investment Consulting Co. The joint venture will make and sell water treatment equipment and components, provide technical consultancy, and support and undertake water treatment engineering projects. According to Hyflux, it opens up opportunities to participate in municipal water treatment projects in a region that is facing a shortage of water, and is host to the Olympic Games in 2008. Ms Olivia Lum, Hyflux Group Chief Executive Officer and President, says: ‘With our combined strengths, this joint venture is positioned to be a strong player in the municipal water market, especially in Beijing and other parts of northern China.’ Hyflux Filtech will hold a 26% interest in the registered capital of the joint-venture company. Contact: Hyflux Group, 202 Kallang Bahru, Hyflux Building, Singapore 339339. Tel: +65 6214 0777, Fax: +65 6214 1211, Email: [email protected], www.hyflux.com
Membrane Technology June 2005